0
Business
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
April 14, 2026
Scroll
Posted 4 hours ago by
ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22, with newer drugs helping offset declines in legacy treat
Quartz
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.